IJAR - Indian Journal of Applied Research

Daniela Trandafir; Violeta Trandafir

Volume : VI, Issue : VI, June - 2016

Intralesional Injection of Bleomycin � First Choice as Treatment Option for Lip Hemangiomas

Daniela Trandafir, Violeta Trandafir

Abstract :

 Bleomycin is a cytotoxic substance discovered about 50 years ago and successfully used today in multiple chemotherapy of some human cancers, but in the last 20 years it has proven its usefulness in the local treatment of some benign lesions (for example, intralesional injection of the vascular tumors). In this paper we present the clinical case of a female patient diagnosed with a hemangioma of the lower lip at the age of adulthood, where two intralesional injections with a solution of Bleomycin were performed at one month interval between them, with very good aesthetic and functional results, only three months after starting therapy. In our opinion, lip hemangioma location requires choosing a treatment method which primarily avoids the facial mutilation and optimally restores the lip functionality, without hurting the facial aesthetics, therefore we consider Bleomycin intralesional injection as first choice therapeutic option to treat lip hemangiomas. When Bleomycin is injected intralesional in lip hemangiomas in much lower doses than those used in systemic chemotherapy of cancer, it will involve minimal side effects and therefore it is a safe substance for the treatment of these injuries, despite its general cytotoxic characteristics.